Maternal use of opioid analgesics just prior to or during early pregnancy is associated with a modestly higher risk of certain birth defects, according to a study published online Feb. 24 in the American Journal of Obstetrics & Gynecology.
WEDNESDAY, March 2 (HealthDay News) -- Maternal use of opioid analgesics just prior to or during early pregnancy is associated with a modestly higher risk of certain birth defects, according to a study published online Feb. 24 in the American Journal of Obstetrics & Gynecology.
Cheryl S. Broussard, Ph.D., of the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues evaluated whether maternal opioid treatment between one month before pregnancy and the first trimester was associated with birth defects. They used data from the National Birth Defects Prevention Study (1997 to 2005).
The investigators found that opioid use was reported by 2.6 percent of 17,449 case mothers and 2.0 percent of 6,701 control mothers. Maternal opioid treatment was statistically significantly associated with conoventricular septal defects (odds ratio [OR], 2.7), atrioventricular septal defects (OR, 2.0), hypoplastic left heart syndrome (OR, 2.4), spina bifida (OR, 2.0), or gastroschisis (OR, 1.8) in infants.
"It's important to acknowledge that although there is an increased risk for some types of major birth defects from an exposure to opioid analgesics, that absolute risk for any individual woman is relatively modest," Broussard said in a statement. "However, with very serious and life threatening birth defects like hypoplastic left heart syndrome, the prevention of even a small number of cases is very important."
Related Content
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
Similar delivery times between misoprostol dosages among obese patients reported
May 29th 2024A recent study found that obese patients undergoing induction of labor experienced similar delivery times regardless of whether they received 50 μg or 25 μg of vaginal misoprostol, though multiparous patients showed faster delivery with the higher dosage.
Read More
Buprenorphine use in pregnancy linked to decreased fetal breathing movements
May 18th 2024According to a poster presented at ACOG 2024, use of the synthetic opioid buprenorphine depressed fetal breathing in biophysical profile assessments, but had no significant impact on other factors like amniotic fluid index or fetal tone.
Read More